Gain Therapeutics

Gain Therapeutics

Biotechnology, 4800 Hampden Ln Ste 200, Bethesda, Maryland, 20814, United States, 11-50 Employees

gaintherapeutics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 30********

Who is GAIN THERAPEUTICS

Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, SEE-TxTM...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GAIN THERAPEUTICS

Gain Therapeutics Org Chart and Mapping

Matthias Alder

Chief Executive Officer

Employees

Roshan Ahmed

Director, Business Development

Danielle Clay

Senior Director of Human Resources

Mariah Sciacca

Executive Assistant to Chief Executive Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Gain Therapeutics

Answer: Gain Therapeutics's headquarters are located at 4800 Hampden Ln Ste 200, Bethesda, Maryland, 20814, United States

Answer: Gain Therapeutics's phone number is 30********

Answer: Gain Therapeutics's official website is https://gaintherapeutics.com

Answer: Gain Therapeutics's revenue is $1 Million to $5 Million

Answer: Gain Therapeutics's SIC: 2836

Answer: Gain Therapeutics's NAICS: 541714

Answer: Gain Therapeutics has 11-50 employees

Answer: Gain Therapeutics is in Biotechnology

Answer: Gain Therapeutics contact info: Phone number: 30******** Website: https://gaintherapeutics.com

Answer: Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, SEE-TxTM, is a novel approach that uses structural and computational biology to discover previously unidentified allosteric binding sites with high potential for druggability. These sites can be targeted with small molecules for therapeutic benefit to correct enzyme misfolding, thereby restoring function, eliminating toxic substrate, and addressing the underlying cause of disease. SEE-TxTM is an entirely new drug discovery and development process made possible by Supercomputing with the potential to transform this process into a more efficient method with life changing treatments created in a fraction of the time at a fraction of the cost and for multiple disease target. The platform has generated all of the development candidates currently in Gains pipeline. Gain has an initial focus in lysosomal storage diseases and CNS disorders, but the platform is agnostic and can be applied to any disease caused by protein misfolding, including the disease areas of metabolism, immunology, and oncology. The company has an experienced and highly successful Board of Directors and management team with over $30 billion in transactional history.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access